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Background: Influenza vaccines are most effective when the antigens in the vaccine match those of circulating
influenza strains. The extent to which the vaccine is protective when circulating strains differ from vaccine antigens,
or are mismatched, is uncertain. We propose to systematically review the cross-protection offered by influenza
vaccines against circulating influenza A or B viruses that are not antigenically well-matched to vaccine strains.
Methods/Design: This is a protocol for a systematic review and meta-analysis. Placebo-controlled randomized
clinical trials (RCTs) reporting laboratory-confirmed influenza among healthy participants vaccinated with antigens
of influenza strains that differed from those circulating will be included. The primary outcome is the incidence of
laboratory-confirmed influenza (polymerase chain reaction (PCR) or viral culture). The secondary outcome is the
incidence of laboratory-confirmed influenza through antibody assay (a less sensitive test than PCR or viral culture)
alone or combined with PCR, and/ or viral culture. The review will be limited to RCTs written in English.
We will search MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, previous influenza reviews, and
the reference lists of included studies to identify potentially relevant RCTs. Two independent reviewers will conduct
all levels of screening, data abstraction, and quality appraisal (using the Cochrane risk of bias tool).
If appropriate, random effects meta-analysis of vaccine efficacy will be conducted in SAS (version 9.2) by calculating
the relative risk. Vaccine efficacy will be calculated using the following formula: (1 - relative risk × 100). The results
will be analyzed by type of vaccine (live attenuated, trivalent inactivated, or other). Subgroup analysis will include
the effects of age (children, adults, older participants), and influenza A versus influenza B on the results. For
influenza B we will also consider variable degrees of antigenic mismatch (lineage and drift mismatch).
Discussion: Our results can be used by researchers and policy-makers to help predict the efficacy of influenza
vaccines during mismatched influenza seasons. Furthermore, the review will be of interest to patients and clinicians
to determine whether to get immunized or support immunization for a particular influenza season.
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VaccinesBackground
Influenza causes a substantial medical and economic
burden to society. In the US alone, approximately 31
million outpatient visits each year and approximately 3.1
million hospitalized days are attributable to influenza
[1]. Direct medical costs related to influenza averaged
US$10.4 billion in 2003 and the estimated lost earnings
as a result of illness and loss of life accounted for US* Correspondence: loebm@mcmaster.ca
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reproduction in any medium, provided the or$16.3 billion [1]. The loss of productivity and time away
from work can potentially hinder economic growth. For
example, one study found that influenza and influenza-
like illnesses accounted for 17.7% (1,389 of 7,868 days)
of employee absenteeism [2].
Influenza is often diagnosed using clinical symptoms
or signs, such as fever, respiratory illness, and myalgia.
However, the clinical diagnosis of influenza, which is
dependent on the prevalence of circulating influenza in
the community, can be limited [3]. Diagnostic tests
available for influenza include viral culture, serology,
polymerase chain reaction (PCR), immunofluorescencetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cificity of all influenza diagnostic tests will vary by la-
boratory, type of test used, and type of specimen tested.
However, PCR has emerged as the most reliable test that
can be used in clinical care and research.
The most effective way to prevent influenza is vaccin-
ation. Safe and effective vaccines have been available and
used for more than 60 years. Currently, the two major
types of vaccine classification are trivalent inactivated
vaccines (TIV) and live attenuated influenza vaccines
(LAIV). Although previous reviews have examined the
efficacy of these vaccines [4-6], none have focused on
vaccine efficacy when circulating strains do not match
the vaccine composition. Furthermore, previous reviews
have not provided estimates of matched and mismatched
vaccine efficacy specifically for influenza A and influenza
B, which have different biological characteristics.
In this proposal, we describe a strategy to systematic-
ally review the crossprotection offered by influenza vac-
cines, which can be defined as protection against
circulating influenza A or B viruses that are not antige-
nically wellmatched to the vaccine strains. Specifically,
our research question is ‘what is the crossprotection
afforded by vaccination (using an LAIV, TIV, or other
type of vaccine) against influenza A or B and their sub-
types and lineages?’
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) Statement will be used to
guide the reporting and conduct of this review [7]. The
systematic review protocol was registered with the
PROSPERO database (registration number
CRD42012001926).
Eligibility criteria
Healthy children, adults or older participants were
chosen as our population of interest. Influenza vaccines
may be ineffective in immune-compromised individuals
and those with chronic health conditions; therefore we
will focus on healthy individuals. All influenza vaccines
will be included, and will be categorized as TIV, LAIV,
and others (that is, non-TIV or non-LAIV).
The eligibility criteria will be limited to randomized
clinical trials (RCTs) and quasi-RCTs comparing influ-
enza vaccine(s) with placebo. To be included, the RCTs
must report data on the primary or secondary outcomes.
The primary outcome is the incidence of laboratory-
confirmed influenza identified by PCR or viral culture
[8]. We will not include studies using rapid influenza
diagnostic tests, as their sensitivity is low (especially dur-
ing flu season) and false positives are common during
low activity seasons [8]. Furthermore, we will not in-
clude laboratory-confirmed influenza through antibodyassay as part of the primary outcome, as this is a less
sensitive test than PCR and viral culture [8]. The sec-
ondary outcomes are laboratory-confirmed influenza
identified by 1) antibody assay or 2) influenza infection
determined by antibody assay, PCR, and/or viral culture.
Inclusion of studies will not be limited by publication
status or year of dissemination, however, only RCTs
written in English will be included. The draft eligibility
form can be found in Additional file 1: Appendix 1.Study selection process
The results from the literature search will be uploaded
to online proprietary systematic review software (Sys-
RevTool) available through the Li Ka Shing Knowledge
Institute of St. Michael’s Hospital. This software will be
used for screening the citations from the electronic data-
base, as well as all full-text articles identified through
the search.
To ensure reliability, a training exercise will be con-
ducted prior to commencing the screening process.
Using the inclusion and exclusion criteria, a random
sample of 50 citations from the literature search will be
screened by all reviewers. Inter-rater agreement will be
calculated using a kappa statistic and percent agreement
[9]. If poor to moderate agreement is observed (that is, a
kappa statistic less than 0.6 or percentage agreement less
than 60%), the inclusion and exclusion criteria will be
revised as necessary.
Using the final relevance form, two reviewers will
screen the literature search results for inclusion, inde-
pendently. They will then independently review the full
text of potentially relevant articles and screen them to
determine inclusion using the same inclusion and exclu-
sion criteria. Conflicts will be resolved by discussion or
the involvement of a third reviewer.Information sources and search
Literature search strategies will be developed using med-
ical subject headings (MeSH) and text words related to
influenza vaccination. We will search MEDLINE (OVID
interface, 1948 onwards), EMBASE (OVID interface,
1980 onwards), and the Cochrane Central Register of
Controlled Trials (Wiley interface, current issue). The
electronic database search will be supplemented by
searching for trial protocols through metaRegister
(http://www.controlled-trials.com/mrct/). The literature
search will be limited to the English language and
human subjects.
To ensure literature saturation, we will scan the refer-
ence lists of included studies or relevant reviews identi-
fied through the search. We will also search the authors’
personal files to make sure that all relevant material has
been captured. Finally, we will circulate a bibliography of
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well as to influenza experts identified by the team.
An experienced information specialist (Dr. Jessie
McGowan) will conduct all of the literature searches.
The search strategy will be peer reviewed by another li-
brarian using the Peer Review of Electronic Search Strat-
egies (PRESS) checklist [10]. The search strategy for the
main electronic database search in MEDLINE is pre-
sented in Additional file 2: Appendix 2.
Data items
The data abstracted will include study characteristics
(for example, year of conduct, sample size, setting, coun-
try of conduct, circulating viral strain(s), vaccine com-
position, viral strain(s) tested, infection detection
method (for example, PCR, viral culture, assay type, type
of vaccines examined); participant characteristics (for ex-
ample, population, mean age and standard deviation,
percent gender); and number of influenza infections per
treatment group.
Data collection process
A draft data abstraction form will be developed, piloted,
and modified as necessary. To ensure data accuracy, two
reviewers will independently abstract all of the data
using the standardized data abstraction form. Discrepan-
cies will be resolved by discussion amongst the review
team.
We suspect that in some instances, multiple study
publications will report data from the same population
(that is, companion reports). When this occurs, the re-
port with the largest sample size or longest duration of
follow-up will be included and will be used to abstract
data. The other report(s) will be used for supplementary
data only. We will contact the study author(s) for further
information when the data are not clearly reported.
Risk of bias appraisal
We will appraise the risk of bias in the RCTs using the
Cochrane risk of bias tool [12]. This tool is composed of
the following seven items: selection bias (random se-
quence generation and allocation concealment), per-
formance bias (blinding of participants and personnel),
detection bias (blinding of outcome assessment), attri-
tion bias (incomplete outcome data), reporting bias (se-
lective outcome reporting), and other sources of bias.
For the selective outcome reporting criterion, the RCT
protocols will be searched for using the metaRegister
database (http://www.controlled-trials.com/mrct) and
the outcomes reported in the protocol will be compared
to those reported in the final RCT publication. Industry-
funded RCTs will be scored as ‘unclear’ for the other
sources of bias criterion, due to the potential for funding
bias [12].Synthesis of included studies
The data will first be summarized descriptively. If appro-
priate, pooled estimates of influenza illness will be
derived using a random effects model [13] to calculate
the relative risk. Vaccine efficacy will be calculated using
the following formula: (1 - relative risk × 100). Separate
meta-analyses will be conducted for the different types
of influenza vaccine (that is, TIV, LAIV, other). Planned
subgroup analyses include age group (children, adults,
and older participants) and type of influenza (A versus
B). Random effects meta-analyses will be conducted using
SAS (SAS v9.2, SAS Institute, Cary, NC, USA) [13]. If ex-
tensive statistical heterogeneity is observed (for example, a
statistically significant Cochran Q test for heterogeneity or
an I2 statistic greater than 60% [12]) and the number of
studies for outcomes of interest is greater than 10, we will
conduct meta-regression analysis. The meta-regression
analysis will explore the influence of factors such as age
and baseline antibody levels on the meta-analysis results
and will also be conducted in SAS [12].
Discussion
This systematic review will comprehensively examine
the extent to which influenza vaccines protect against
non-matching circulating strains. Although previous in-
fluenza reviews exist [4-6,14], none have focused specif-
ically on this issue. Furthermore, we will examine the
degree of cross-protection separately for influenza A and
influenza B, which has not been estimated previously.
The results can be used by researchers and policy-
makers to help predict the efficacy of influenza vaccines
when they do not match circulating strains for a particu-
lar influenza season. Patients can use this information to
decide whether to obtain the influenza vaccine and clini-
cians can use this information to decide whether to rec-
ommend the influenza vaccine for a particular season.
This work will also provide valuable information to help
inform the development of improved seasonal influenza
vaccines.
This review is currently under way and there have
been some changes to the protocol over time. The scope
of the review, originally included crossprotection after
vaccination and natural infection, however, after much
deliberation, the team felt that this scope was too broad.
Natural infection and vaccination are fundamentally dif-
ferent entities, with different types of studies examining
each one. Therefore, it was decided to focus on vaccin-
ation only, thus narrowing the scope of the review. Fur-
thermore, we initially planned to only include mismatch
estimates of vaccine cross protection against influenza A
and B. However, we discovered that little information is
known about the matched vaccine efficacy estimates for
influenza A and B separately. This information is not
reported in previous influenza vaccine efficacy reviews,
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fluenza A and B [4-6,14]. By conducting this additional
analysis, we can clearly compare matched versus mis-
matched vaccine efficacy against influenza A and influ-
enza B separately. Such distinctions will be important
since it will be possible to explore the antigenic hetero-
geneity that exists within each subtype of influenza and
the relevant impact on vaccine development.
Data on mismatch is not normally available in the title
and abstract, therefore, all influenza trials were passed
onto level 2 screening. As such, it was easy for the team
to quickly go through the studies that were excluded at
level 2 to identify the respective RCTs conducted during
influenza seasons with matching circulating strains and
vaccine composition.
The original plan was to conduct a systematic review
on all years but it was felt that using the three Cochrane
reviews on influenza vaccine efficacy among adults [4],
older participants [5], and children [6] as a starting point
would be a more efficient approach. The inclusion and
exclusion criteria of the Cochrane reviews were consist-
ent with the proposed review so it was felt that there
was no sense in going back further in time. The team
decided to obtain all of the included and excluded arti-
cles in the Cochrane reviews to make sure that poten-
tially relevant material was not missed. Furthermore, all
data obtained from the studies included in Cochrane
were abstracted in duplicate by two reviewers to ensure
accuracy (that is, we did not rely on the estimates pub-
lished in the Cochrane reviews).
The literature searches were conducted from March
2006 (date of the most outdated Cochrane review search)
until August 2011. They will be updated to February 1,
2012, to ensure all potentially relevant material is cap-
tured. The updated literature search will be conducted by
Laure Perrier, an information specialist working with St.
Michael’s Hospital, using the peer-reviewed literature
search originally compiled by Dr. Jessie McGowan.
After reviewing another systematic review examining
influenza vaccine effectiveness [15] the team came up
with a sensitivity analysis for meta-analysis. This
included the classification of influenza B mismatch into
two different types: (1) mismatch due to within-lineage
drift and (2) complete lineage mismatch (that is, B/
Yamagata versus B/Victoria lineages) between the vac-
cine and the circulating strains. This will help explore
antigenic heterogeneity related to influenza B and its im-
pact on vaccine efficacy when using a mismatched vac-
cine, important information for vaccine development.Additional files
Additional file 1: Appendix 1. Draft eligibility criteria.Additional file 2: Appendix 2. Draft medline search strategy.
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